天合光能(688599.SH):興銀資本、興璟投資以大宗交易合計減持1.82%的股份
格隆匯11月9日丨天合光能(688599.SH)公佈,公司於2022年11月9日收到興銀資本、興璟投資的減持吿知函,興銀資本於2022年8月5日至2022年11月9日期間通過大宗交易方式減持公司股份共計2779.62萬股,興璟投資於2022年8月5日至2022年11月9日期間通過大宗交易方式減持公司股份共計1162.69萬股。
截至2022年11月9日,興銀資本及其一致行動人興璟投資持有的公司股份從303,198,193股減少至263,775,093股,減持比例佔公司目前總股本的1.82%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.